UB Paderborn / Katalog / Suche / in CDI

Response to Comment on: Bergenstal et al. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care 2012;35:2140-2147

Diabetes care, 2013-07, Vol.36 (7), p.e107-e108

2013

Link zum Volltext

Verfügbarkeit prüfen

Novel PEGylated Basal Insulin LY2605541 Has a Preferential Hepatic Effect on Glucose Metabolism

Diabetes (New York, N.Y.), 2014-02, Vol.63 (2), p.494-504

2014

Link zum Volltext

Verfügbarkeit prüfen

A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin―Treated Patients With Type 2 Diabetes

Diabetes care, 2012-11, Vol.35 (11), p.2140-2147

2012

Link zum Volltext

Verfügbarkeit prüfen

Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study

Diabetes care, 2013-03, Vol.36 (3), p.522-528

2013

Link zum Volltext

Verfügbarkeit prüfen

Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy Subjects

Diabetes care, 2014-09, Vol.37 (9), p.2609-2615

2014

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of the Long-Acting Basal Insulin LY2605541 in Subjects With Varying Degrees of Renal Function

Clinical pharmacology in drug development, 2016-05, Vol.5 (3), p.216-224

2016

Link zum Volltext

Verfügbarkeit prüfen

Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug–drug interaction trials

British journal of clinical pharmacology, 2010-10, Vol.70 (4), p.523-536

2010

Link zum Volltext

Verfügbarkeit prüfen

Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes

Diabetes care, 2013-03, Vol.36 (3), p.522-528

2013

Link zum Volltext

Verfügbarkeit prüfen

Safety, Tolerability, QTc Evaluation, and Pharmacokinetics of Single and Multiple Doses of Enzastaurin HCl (LY317615), a Protein Kinase C-{szligbeta} Inhibitor, in Healthy Subjects

Journal of clinical pharmacology, 2007-09, Vol.47 (9), p.1138-1151

2007

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance

Clinical cancer research, 2018-12, Vol.24 (23), p.5841-5849

2018

Link zum Volltext

Verfügbarkeit prüfen

Suicide mortality in India: a nationally representative survey

The Lancet (British edition), 2012-06, Vol.379 (9834), p.2343-2351

2012

Link zum Volltext

Verfügbarkeit prüfen

Extraction and Purification of Lectin from Soybean Seeds (Glycine max)

Letters in Applied NanoBioScience, 2023-12, Vol.12 (4), p.100

2023

Link zum Volltext

Verfügbarkeit prüfen

Corrigendum to “A six-weekly (Q6W) dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation” [Eur J Canc 131 (2020) 68–75]

European journal of cancer (1990), 2021-02, Vol.144, p.400-400

2021

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic Development in Polyarticular Course Juvenile Idiopathic Arthritis: Extrapolation, Dose Selection, and Clinical Trial Design

Arthritis & rheumatology (Hoboken, N.J.), 2023-10, Vol.75 (10), p.1856-1866

2023

Link zum Volltext

Verfügbarkeit prüfen

Water Resource Technology: Management for Engineering Applications

1, 2021

Link zum Volltext

Verfügbarkeit prüfen

The Structural Basis for the Prevention of Nonsteroidal Antiinflammatory Drug-Induced Gastrointestinal Tract Damage by the C-Lobe of Bovine Colostrum Lactoferrin

Biophysical journal, 2009-12, Vol.97 (12), p.3178-3186

2009

Link zum Volltext

Verfügbarkeit prüfen

THE CRITICAL PATH FOR ALZHEIMER’S DISEASE: HIPPOCAMPAL VOLUME AS AN ENRICHMENT BIOMARKER IN TRIALS OF PATIENTS WITH MILD COGNITIVE IMPAIRMENT

Alzheimer's & dementia, 2018-07, Vol.14 (7), p.P1076-P1076

2018

Link zum Volltext

Verfügbarkeit prüfen

P3‐031: THE CRITICAL PATH FOR ALZHEIMER'S DISEASE: HIPPOCAMPAL VOLUME AS AN ENRICHMENT BIOMARKER IN TRIALS OF PATIENTS WITH MILD COGNITIVE IMPAIRMENT

Alzheimer's & dementia, 2018-07, Vol.14 (7S_Part_20), p.P1076-P1076

2018

Link zum Volltext

Verfügbarkeit prüfen

THE COALITION AGAINST MAJOR DISEASES: TOWARD U.S. FDA QUALIFICATION OF HIPPOCAMPAL VOLUME AS A BIOMARKER FOR ENRICHMENT IN CLINICAL TRIALS FOR PRE-DEMENTIA STAGES OF ALZHEIMER'S DISEASE

Alzheimer's & dementia, 2017-07, Vol.13 (7), p.P1259-P1259

2017

Link zum Volltext

Verfügbarkeit prüfen

Homeopathy in chronic sinusitis: a prospective multi-centric observational study

Homeopathy : the journal of the Faculty of Homeopathy, 2012-04, Vol.101 (2), p.84

2012

Link zum Volltext

Verfügbarkeit prüfen

Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop

Journal of pharmacokinetics and pharmacodynamics, 2014-12, Vol.41 (6), p.545-552

2014

Link zum Volltext

Verfügbarkeit prüfen

Diagnosis of Prostate Cancer with Support Vector Machine Using Multiwavelength Photoacoustic Images

Proceedings of 3rd International Conference on Computer Vision and Image Processing, 2019, Vol.1022, p.247-254

2019

Link zum Volltext

Verfügbarkeit prüfen

Structural and binding studies of C-terminal half (C-lobe) of lactoferrin protein with COX-2-specific non-steroidal anti-inflammatory drugs (NSAIDs)

Archives of biochemistry and biophysics, 2010-08, Vol.500 (2), p.196-202

2010

Link zum Volltext

Verfügbarkeit prüfen

Specific interactions of C-terminal half (C-lobe) of lactoferrin protein with edible sugars: Binding and structural studies with implications on diabetes

International journal of biological macromolecules, 2010-07, Vol.47 (1), p.50-59

2010

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Response to Comment on: Bergenstal et al. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care 2012;35:2140-2147

Novel PEGylated Basal Insulin LY2605541 Has a Preferential Hepatic Effect on Glucose Metabolism

A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin―Treated Patients With Type 2 Diabetes

Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study

Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy Subjects

Pharmacokinetics of the Long-Acting Basal Insulin LY2605541 in Subjects With Varying Degrees of Renal Function

Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug–drug interaction trials

Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes

Safety, Tolerability, QTc Evaluation, and Pharmacokinetics of Single and Multiple Doses of Enzastaurin HCl (LY317615), a Protein Kinase C-{szligbeta} Inhibitor, in Healthy Subjects

Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance

Suicide mortality in India: a nationally representative survey

Competency‐based EEG education: a list of “must‐know” EEG findings for adult and child neurology residents

Extraction and Purification of Lectin from Soybean Seeds (Glycine max)

Corrigendum to “A six-weekly (Q6W) dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation” [Eur J Canc 131 (2020) 68–75]

Therapeutic Development in Polyarticular Course Juvenile Idiopathic Arthritis: Extrapolation, Dose Selection, and Clinical Trial Design

Water Resource Technology: Management for Engineering Applications

The Structural Basis for the Prevention of Nonsteroidal Antiinflammatory Drug-Induced Gastrointestinal Tract Damage by the C-Lobe of Bovine Colostrum Lactoferrin

THE CRITICAL PATH FOR ALZHEIMER’S DISEASE: HIPPOCAMPAL VOLUME AS AN ENRICHMENT BIOMARKER IN TRIALS OF PATIENTS WITH MILD COGNITIVE IMPAIRMENT

P3‐031: THE CRITICAL PATH FOR ALZHEIMER'S DISEASE: HIPPOCAMPAL VOLUME AS AN ENRICHMENT BIOMARKER IN TRIALS OF PATIENTS WITH MILD COGNITIVE IMPAIRMENT

THE COALITION AGAINST MAJOR DISEASES: TOWARD U.S. FDA QUALIFICATION OF HIPPOCAMPAL VOLUME AS A BIOMARKER FOR ENRICHMENT IN CLINICAL TRIALS FOR PRE-DEMENTIA STAGES OF ALZHEIMER'S DISEASE

Homeopathy in chronic sinusitis: a prospective multi-centric observational study

Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop

Diagnosis of Prostate Cancer with Support Vector Machine Using Multiwavelength Photoacoustic Images

Structural and binding studies of C-terminal half (C-lobe) of lactoferrin protein with COX-2-specific non-steroidal anti-inflammatory drugs (NSAIDs)

Specific interactions of C-terminal half (C-lobe) of lactoferrin protein with edible sugars: Binding and structural studies with implications on diabetes

Aktive Filter

Suchergebnisse filtern